Investigator Perspectives on the Current and Future Management
of Newly Diagnosed Ovarian Cancer — Part 2: Our most recent
one-on-one interview with Professor Ledermann featuring emerging
research and cases from his practice:
Biology and histopathologic subtypes of ovarian cancer
(0:00)
Structure of gynecologic oncology clinical practice in the
United Kingdom (1:58)
Approach to mutation testing for patients with newly diagnosed
ovarian cancer (4:06)
Primary debulking surgery versus neoadjuvant systemic therapy
in the up-front management of advanced ovarian cancer (6:51)
Value of neoadjuvant chemotherapy versus up-front debulking
surgery followed by adjuvant chemotherapy (10:08)
Higher incidence of visceral metastases in patients with
ovarian cancer and BRCA1/2 mutations (13:02)
Optimal timing of debulking surgery with (neo)adjuvant
chemotherapy for newly diagnosed ovarian cancer (15:22)
Efficacy and safety of bevacizumab-containing neoadjuvant
therapy followed by interval debulking surgery for advanced ovarian
cancer; duration of maintenance therapy with bevacizumab
(16:42)
ICON8: Results of a Phase III trial evaluating response to
neoadjuvant weekly dose-dense chemotherapy as first-line therapy
for epithelial ovarian cancer (19:18)
Influence of performance status and age on the choice of
neoadjuvant versus adjuvant chemotherapy (21:07)
Activity and ongoing investigation of PARP inhibitors in
combination with chemotherapy and/or bevacizumab and as maintenance
therapy for patients with newly diagnosed ovarian cancer with and
without germline BRCA mutations (23:12)
Consideration of bevacizumab as a component of (neo)adjuvant
systemic therapy for patients with ovarian cancer (26:41)
Choosing between bevacizumab and olaparib after primary
debulking surgery; importance of timely BRCA mutation analysis to
aid in this decision (29:21)
Progression-free survival benefit with bevacizumab in
combination with and after chemotherapy for patients with
surgically debulked disease (33:15)
Incidence of gastrointestinal toxicities with up-front
bevacizumab for ovarian cancer (36:28)
Approach to discontinuation of maintenance bevacizumab before
surgery (38:13)
MSI/DNA mismatch repair testing in ovarian cancer (39:28)
PARP inhibitor-associated insomnia (40:32)
Case: A woman in her late 50s is
diagnosed with Stage IV high-grade serous ovarian cancer with a
germline BRCA1 mutation
(42:05)
Counseling patients with ovarian cancer with germline BRCA
mutations who did not receive PARP inhibition as a component of
initial therapy about potential use of these agents in future
treatment (45:51)
Impact of BRCA mutation status on patient prognosis and
potential responsiveness to platinum-based chemotherapy
(48:05)
Case: A woman in her early 70s with Stage IV
high-grade serous ovarian cancer with a germline BRCA1 mutation
receives olaparib on the Phase III SOLO-1 trial
(49:21)
Case: A woman in her early 60s with
suboptimally debulked Stage IV high-grade serous ovarian cancer
receives adjuvant chemotherapy/bevacizumab followed by maintenance
bevacizumab (53:03)
Biologic rationale for and ongoing evaluation of
anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors for
newly diagnosed ovarian cancer (56:35)
Benefits and limitations of commercially available HRD
(homologous recombination deficiency) testing platforms
(59:37)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.